摘要
AbstractThe coronavirus disease 2019 (COVID-19) pandemic has highlighted the practice of infectious diseases biobanking, as well as existing challenges and opportunities. Thus, the future of infectious diseases biobanking in the post-pandemic era, shall not be an "entry-level version" of its counterpart in non-communicable diseases and large population cohorts, but incorporate the lessons learned. Biobanks constitute a critical research infrastructure supported by harmonized practices through the implementation of international standards, and perceived within the broader scope of healthcare's intersection with research. This perspective paper considers the barriers in biobanking and standardization of practices, as well as the emerging opportunities in the field.
机构地区
Director of Biobank, G42 Healthcare, Abu Dhabi, United Arab Emirates,Université Cote d’Azur, Nice 06100, France,International Agency for Research on Cancer, World Health Organization, 69372 Lyon CEDEX 08, France
出版日期
2022年12月13日（中国期刊网平台首次上网日期，不代表论文的发表时间）
